| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Aceclofenac and methotrexate combination therapy could influence Th1/Th17 axis to modulate rheumatoid-arthritis-induced inflammation
|
Negi, Sushmita
|
|
|
28 |
8 |
p.
|
artikel
|
| 2 |
Advances in cell-penetrating poly(disulfide)s for intracellular delivery of therapeutics
|
Wan, Yu
|
|
|
28 |
8 |
p.
|
artikel
|
| 3 |
Advances of computer-aided drug design (CADD) in the development of anti-Azheimer’s-disease drugs
|
Niu, Yuzhen
|
|
|
28 |
8 |
p.
|
artikel
|
| 4 |
A perspective on the changing landscape of HTS
|
Lanne, Alice
|
|
|
28 |
8 |
p.
|
artikel
|
| 5 |
Artificially engineered bacteria to treat gastrointestinal disease and cancer
|
Liu, Yong
|
|
|
28 |
8 |
p.
|
artikel
|
| 6 |
Challenges and advances in antimicrobial peptide development
|
Botelho Sampaio de Oliveira, Kamila
|
|
|
28 |
8 |
p.
|
artikel
|
| 7 |
Clinical research with targeted drugs in paediatric oncology
|
Valle-Simón, Paula
|
|
|
28 |
8 |
p.
|
artikel
|
| 8 |
Contents page
|
|
|
|
28 |
8 |
p.
|
artikel
|
| 9 |
Corrigendum to “Pharmacological modulation of autophagy for epilepsy therapy: Opportunities and obstacles” [Drug Discov. Today 28(6) (2023) 103600]
|
Chen, Wenqing
|
|
|
28 |
8 |
p.
|
artikel
|
| 10 |
Corrigendum to “The European Lead Factory: An updated HTS compound library for innovative drug discovery” [Drug Discov. Today 26(10) (2021) 2406–2413]
|
van Vlijmen, Herman
|
|
|
28 |
8 |
p.
|
artikel
|
| 11 |
CRISPR-Cas9 in Alzheimer’s disease: Therapeutic trends, modalities, and challenges
|
Chacko, Leena
|
|
|
28 |
8 |
p.
|
artikel
|
| 12 |
Evaluating the status of antibiotic approvals and readiness to combat antimicrobial resistance: What else can we do better?
|
Oo, Charles
|
|
|
28 |
8 |
p.
|
artikel
|
| 13 |
Global biomarker trends in Alzheimer’s research: A bibliometric analysis
|
Noda, Kenta
|
|
|
28 |
8 |
p.
|
artikel
|
| 14 |
Glypican1: A potential cancer biomarker for nanotargeted therapy
|
Tripathi, Abhay Dev
|
|
|
28 |
8 |
p.
|
artikel
|
| 15 |
Harnessing aptamers against COVID-19: A therapeutic strategy
|
Mahmoudi, Ali
|
|
|
28 |
8 |
p.
|
artikel
|
| 16 |
Hippo signaling in acute kidney injury to chronic kidney disease transition: Current understandings and future targets
|
Habshi, Tahib
|
|
|
28 |
8 |
p.
|
artikel
|
| 17 |
Industry perspective on the nonclinical safety assessment of heterobifunctional degraders
|
Hemkens, Michelle
|
|
|
28 |
8 |
p.
|
artikel
|
| 18 |
2022 in review: FDA approvals of new medicines
|
Kinch, Michael S.
|
|
|
28 |
8 |
p.
|
artikel
|
| 19 |
Modulating GPCR and 14-3-3 protein interactions: Prospects for CNS drug discovery
|
Kongsamut, Sathapana
|
|
|
28 |
8 |
p.
|
artikel
|
| 20 |
PD-1/PD-L1 immune checkpoint blockade in ovarian cancer: Dilemmas and opportunities
|
Peng, Zikun
|
|
|
28 |
8 |
p.
|
artikel
|
| 21 |
Perspectives of data science in preclinical safety assessment
|
Steger-Hartmann, Thomas
|
|
|
28 |
8 |
p.
|
artikel
|
| 22 |
Podophyllotoxin derivatives targeting tubulin: An update (2017–2022)
|
Xu, Yuqin
|
|
|
28 |
8 |
p.
|
artikel
|
| 23 |
Quantum computing for near-term applications in generative chemistry and drug discovery
|
Pyrkov, Alexey
|
|
|
28 |
8 |
p.
|
artikel
|
| 24 |
Recent trends and updates on ultradeformable and elastic vesicles in ocular drug delivery
|
Srivastava, Vaibhavi
|
|
|
28 |
8 |
p.
|
artikel
|
| 25 |
Serendipity in research and development: The promise of putting into place patterns for paying attention
|
Thompson, David C.
|
|
|
28 |
8 |
p.
|
artikel
|
| 26 |
Targeted combination therapies in oncology: Challenging regulatory frameworks designed for monotherapies in Europe
|
Vancoppenolle, Julie M.
|
|
|
28 |
8 |
p.
|
artikel
|
| 27 |
Targeting ATM and ATR for cancer therapeutics: Inhibitors in clinic
|
Priya, Bhanu
|
|
|
28 |
8 |
p.
|
artikel
|
Tijdschrift beschrijving